Psoriatic Arthritis News

Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Patients treated with interleukin-23i or IL-12/23i for psoriasis exhibited similar rates of risk for developing psoriatic arthritis, according to a study.

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.